Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Selecta and Takeda enter strategic licensing agreement for lysosomal storage disorders

Oct. 5, 2021

Modulating PPM1E is a therapeutic approach in type 2 diabetes

Oct. 5, 2021

Dare Bioscience awarded NICHD grant for DARE-LARC1 user-controlled contraceptive

Sep. 28, 2021

Discovery of novel EP3 receptor antagonists

Sep. 27, 2021

Servier discovers nuclear factor erythroid 2-related factor 2 activators

Sep. 27, 2021

Kallyope presents new free fatty acid FFA1 receptor agonists

Sep. 27, 2021

Lymph dysfunction identified as potential metabolic target

Sep. 23, 2021

Kyoto University develops sequence-selective mitochondrial DNA alkylators for mitochondrial diseases

Sep. 22, 2021

Clarus licenses rights to McGill technology to treat conditions associated with CoQ10 deficiencies

Sep. 17, 2021

Novel potent TGR5 agonist shows antidiabetic effects in TGR5(H88Y) mutant mice

Sep. 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.